Phaseline

Companies › Rocket Pharmaceuticals

Rocket Pharmaceuticals: clinical trials, targets and expected readouts

4 active drug programs in 4 registered trials: 2 Phase 1, 2 Phase 2; Cardiovascular, Hematology; next expected readout Jun 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
RP-A501
rAAV9 gene therapy delivering human LAMP2B transgene
LAMP2Phase 2Danon DiseaseJun 2028
RP-L102
Lentiviral vector-mediated ex vivo gene transfer of FANCA gene into CD34+ hematopoietic st
FANCAPhase 2Fanconi Anemia Complementation Group A–
RP-A601
AAV serotype rh.74 vector encoding human plakophilin 2 (PKP2)
PKP2Phase 1PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)Sep 2028
RP-A701
AAV gene therapy delivering BAG3 transgene via AAVrh.74 capsid
BAG3Phase 1Dilated Cardiomyopathy (DCM)Jun 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04248439RP-L102Phase 2Fanconi Anemia Complementation Group AHematologyMay 2026
NCT06092034RP-A501Phase 2Danon DiseaseCardiovascularJun 2028
NCT05885412RP-A601Phase 1PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)CardiovascularSep 2028
NCT07137338RP-A701Phase 1Dilated Cardiomyopathy (DCM)CardiovascularJun 2029

From the company's SEC filings

Cash and short-term investments of $284m on 2026-06-30; operating cash outflow about $172m a year; runway about 20 months at that burn, to Feb 2028; 0 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Complete response letters from FDA

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

BAG3 (1) FANCA (1) LAMP2 (1) PKP2 (1)

Companies with the same targets

AstraZeneca Affinia Therapeutics Tenaya Therapeutics Lexeo Therapeutics

Companies built like this

Lexeo Therapeutics Nectero Medical Rohto Pharmaceutical Beijing Inno Medicine Kardigan

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.